|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These results support the extended the use of EGFR inhibitors beyond monotherapy in the EGFR-mutated adenocarcinoma setting in combination with FGFR inhibitors for selected patients with increased FGFR1 overexpression and EGFR activation.
|
30639621 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
FGFR1 amplification is more frequent in SCCs than in ADCs.
|
27901003 |
2016 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This paper evaluates FGFR1 expression and gene copy number in adenocarcinomas, squamous cell carcinomas, pleomorphic carcinomas (PLEOMC) and adenosquamous carcinomas (ADSQC) of the lung and also explores the epithelial-mesenchymal transition (EMT) pathway.
|
27194548 |
2016 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
FGFR1 amplification, defined as a ratio of FGFR1:centromere 8 copy numbers ≥ 2.0, was more frequently seen in squamous cell carcinoma (8.9% of 202 interpretable cases) than in adenocarcinoma (1.6% of 308; p<0.0001).
|
26555375 |
2015 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
CHFR expression, analyzed by RNA-seq, was classified as high vs. low based on the median CHFR expression level and correlated with the presence or absence of lung cancer specific mutations (EGFR, KRAS, ALK, MET, ERBB2, TP53, STK11, ROS1, RET, NF1, Pik3CA for adenocarcinomas and FGFR1, FGFR2, FGFR3, TP53, STK11, EGFR for squamous cell carcinomas).
|
25477232 |
2015 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Here, we examined gene copy number of fibroblast growth factor receptor 1 (FGFR1), a potential target for tyrosine kinase inhibitors, and clinicopathologic parameters in a large cohort of gastric adenocarcinomas.
|
26239623 |
2015 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
FGFR1 amplification was found in 32/369 (8.7 %) of NSCLC and was more frequent in SqCC (18.0 % in SqCC, 3.0 % in adenocarcinoma; p < 0.001) and in smokers (p < 0.001).
|
25086725 |
2014 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The prevalence of an FGFR1 amplification was 12.5% (41/329) and was significantly (P<0.0001) higher in squamous cell carcinoma (SCC) (20.7%) than in adenocarcinoma (2.2%) and large cell carcinoma (13%).
|
24853178 |
2014 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In resected tumors, 22% of adenocarcinomas and 28% of SCCs expressed high FGFR1 mRNA.
|
24771645 |
2014 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
FGFR1 amplifications were found in a total of 30/175 (17%) brain metastases: 4/21 (19%) squamous cell carcinomas, 20/130 (15.3%) adenocarcinomas, 2/12 (16.6%) adenosquamous carcinomas, 4/9 (44.4%) large cell carcinomas and 0/3 neuroendocrine large cell carcinoma.
|
24183471 |
2014 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
High FGFR1 gene copy number (amplification or high-level polysomy) was significantly more frequent in squamous cell carcinomas (SCC) (24.8%) and large cell carcinomas (LCC) (25%) compared to adenocarcinomas (11.3%) (p = 0.01 and p = 0.03 respectively).
|
23806793 |
2013 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Genes overexpressed in adenocarcinoma with bronchioloalveolar features included fibroblast growth factor receptor 1, and CLDN18 (claudin 18), whereas those overexpressed in BAC included ataxia telangiectasia and Rad3 related (ataxia telangiectasia mutated and Rad3-related), and activating transcription factor 2.
|
22864788 |
2013 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The rates of FGFR1 amplification using the cutoff level of 3.5 were 5.1% in squamous cell and 4.1% in adenocarcinomas.
|
24255716 |
2013 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
FGFR1 amplifications were observed in 20% of pulmonary squamous carcinomas but not in adenocarcinomas.
|
22684217 |
2012 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The incidence of FGFR1 amplification within Chinese patient NSCLC tumors was 12.5% of squamous origin (6 of 48) and 7% of adenocarcinoma (5 of 76).
|
23082000 |
2012 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The higher FGFR1 gene copy numbers in SCC compared to ADC did not reach statistical significance.
|
22648708 |
2012 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Archived tissue from NSCLC (adenocarcinoma and SCC; n = 321) and adjacent bronchial epithelial specimens (n = 426) were analyzed for the immunohistochemical expression of bFGF, FGFR1, and FGFR2, and the findings were correlated with clinicopathologic features of the patients.
|
18829480 |
2008 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Archived tissue from NSCLC (adenocarcinoma and SCC; n = 321) and adjacent bronchial epithelial specimens (n = 426) were analyzed for the immunohistochemical expression of bFGF, FGFR1, and FGFR2, and the findings were correlated with clinicopathologic features of the patients.
|
18829480 |
2008 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present study, we found elevated expression of fibroblast growth factor (FGF) 2, FGF receptor 1 (FGFR1), and FP receptor, colocalized within the neoplastic epithelial cells of endometrial adenocarcinomas.
|
17478553 |
2007 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present study, we introduced wild-type KGFR cDNA or chimeric KGFR/FGFR1 cDNA, which encoded the extracellular domain of KGFR and the intracellular domain of FGFR1, into the HSY human salivary adenocarcinoma cell line.
|
11562460 |
2001 |